Chronic bupropion attenuated the anhedonic component of nicotine withdrawal in rats via inhibition of dopamine reuptake in the nucleus accumbens shell

Bupropion, a dopamine reuptake inhibitor, is an effective therapy for smoking cessation, but the behavioral and neurochemical mechanisms mediating its antismoking properties are relatively unknown. To explore the hypothesis that bupropion ameliorates nicotine withdrawal partly by a dopamine‐dependen...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:The European journal of neuroscience 2007-05, Vol.25 (10), p.3099-3108
Hauptverfasser: Paterson, Neil E., Balfour, David J., Markou, Athina
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 3108
container_issue 10
container_start_page 3099
container_title The European journal of neuroscience
container_volume 25
creator Paterson, Neil E.
Balfour, David J.
Markou, Athina
description Bupropion, a dopamine reuptake inhibitor, is an effective therapy for smoking cessation, but the behavioral and neurochemical mechanisms mediating its antismoking properties are relatively unknown. To explore the hypothesis that bupropion ameliorates nicotine withdrawal partly by a dopamine‐dependent mechanism, we investigated the effects of chronic bupropion on potassium‐stimulated dopamine overflow in the nucleus accumbens shell in nicotine‐withdrawing rats. We also assessed the effects of chronic bupropion on behavioral aspects of nicotine withdrawal measured by elevations in brain reward thresholds and somatic signs of withdrawal. Rats were treated with nicotine or saline for 7 days and then coadministration of bupropion or saline was initiated. After 14 days of coadministration of bupropion/saline and nicotine/saline, nicotine/saline administration was terminated, whereas bupropion/saline administration continued. These conditions mimic bupropion administration in human smokers. Cessation of nicotine administration in non‐bupropion‐treated rats elevated reward thresholds reflecting a reward deficit, increased somatic signs and diminished potassium‐evoked dopamine overflow in the nucleus accumbens shell. Chronic bupropion lowered reward thresholds and increased potassium‐evoked dopamine release regardless of previous nicotine exposure, possibly by inhibition of dopamine reuptake, and thus attenuated the anhedonic and neurochemical effects of nicotine withdrawal. Chronic bupropion blocked withdrawal‐associated increased somatic signs. Finally, acute experimenter‐administered nicotine enhanced brain reward function equally in all groups, indicating that bupropion does not alter the reward‐facilitating effects of experimenter‐administered nicotine. In conclusion, the bupropion‐induced increase in extracellular dopamine in the nucleus accumbens shell may ameliorate the anhedonia associated with nicotine withdrawal, which in turn may facilitate smoking cessation.
doi_str_mv 10.1111/j.1460-9568.2007.05546.x
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_20526237</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>20526237</sourcerecordid><originalsourceid>FETCH-LOGICAL-c5026-d53b9a2b21a5f9b3b85816f57851384f57d5932b01d898b26f66a24b238693413</originalsourceid><addsrcrecordid>eNqNkU-P1CAYxonRuOPqVzCcvLXyp1B68GAm66hZVxM1eiPQ0pTZFipQZ_aL-HmlO5P1KhfewO954H0fACBGJc7r9b7EFUdFw7goCUJ1iRireHl8BDYPF4_BBjWMFgLznxfgWYx7hJDgFXsKLnDNOBaEbsCf7RC8sy3Uyxz8bL2DKiXjFpVMB9NgoHKD6e6R1k-zd8Yl6HuYD3yyzsCDTUMX1EGN0DoYVIrwt1W5Hqy2aTXMdOdnNa10MMuc1K1Z2dXdLe1olghV2y6TNi7COJhxfA6e9GqM5sV5vwTf3119274vrj_vPmzfXhctQ4QXHaO6UUQTrFjfaKoFy-32rBYMU1HlomMNJRrhTjRCE95zrkilCRW8oRWml-DVyTc3_2sxMcnJxjZ_QDnjlygJYoQTWmdQnMA2-BiD6eUc7KTCncRIrpnIvVxHL9fRyzUTeZ-JPGbpy_Mbi55M9094DiEDb07AwY7m7r-N5dXHm7XK-uKktzGZ44NehVvJa1oz-eNmJz_hese-ftnKHf0LISasaA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>20526237</pqid></control><display><type>article</type><title>Chronic bupropion attenuated the anhedonic component of nicotine withdrawal in rats via inhibition of dopamine reuptake in the nucleus accumbens shell</title><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><creator>Paterson, Neil E. ; Balfour, David J. ; Markou, Athina</creator><creatorcontrib>Paterson, Neil E. ; Balfour, David J. ; Markou, Athina</creatorcontrib><description>Bupropion, a dopamine reuptake inhibitor, is an effective therapy for smoking cessation, but the behavioral and neurochemical mechanisms mediating its antismoking properties are relatively unknown. To explore the hypothesis that bupropion ameliorates nicotine withdrawal partly by a dopamine‐dependent mechanism, we investigated the effects of chronic bupropion on potassium‐stimulated dopamine overflow in the nucleus accumbens shell in nicotine‐withdrawing rats. We also assessed the effects of chronic bupropion on behavioral aspects of nicotine withdrawal measured by elevations in brain reward thresholds and somatic signs of withdrawal. Rats were treated with nicotine or saline for 7 days and then coadministration of bupropion or saline was initiated. After 14 days of coadministration of bupropion/saline and nicotine/saline, nicotine/saline administration was terminated, whereas bupropion/saline administration continued. These conditions mimic bupropion administration in human smokers. Cessation of nicotine administration in non‐bupropion‐treated rats elevated reward thresholds reflecting a reward deficit, increased somatic signs and diminished potassium‐evoked dopamine overflow in the nucleus accumbens shell. Chronic bupropion lowered reward thresholds and increased potassium‐evoked dopamine release regardless of previous nicotine exposure, possibly by inhibition of dopamine reuptake, and thus attenuated the anhedonic and neurochemical effects of nicotine withdrawal. Chronic bupropion blocked withdrawal‐associated increased somatic signs. Finally, acute experimenter‐administered nicotine enhanced brain reward function equally in all groups, indicating that bupropion does not alter the reward‐facilitating effects of experimenter‐administered nicotine. In conclusion, the bupropion‐induced increase in extracellular dopamine in the nucleus accumbens shell may ameliorate the anhedonia associated with nicotine withdrawal, which in turn may facilitate smoking cessation.</description><identifier>ISSN: 0953-816X</identifier><identifier>EISSN: 1460-9568</identifier><identifier>DOI: 10.1111/j.1460-9568.2007.05546.x</identifier><identifier>PMID: 17561823</identifier><language>eng</language><publisher>Oxford, UK: Blackwell Publishing Ltd</publisher><subject>Animals ; brain reward function ; Bupropion - pharmacology ; Bupropion - therapeutic use ; chronic bupropion ; Dopamine - metabolism ; Dopamine Uptake Inhibitors - pharmacology ; Dopamine Uptake Inhibitors - therapeutic use ; Drug Administration Schedule ; extracellular dopamine ; Male ; nicotine withdrawal ; Nucleus Accumbens - drug effects ; Nucleus Accumbens - metabolism ; nucleus accumbens shell ; Potassium - pharmacology ; rat ; Rats ; Rats, Wistar ; Reward ; Substance Withdrawal Syndrome - drug therapy ; Substance Withdrawal Syndrome - metabolism ; Substance Withdrawal Syndrome - physiopathology ; Synaptic Transmission - drug effects ; Synaptic Transmission - physiology ; Tobacco Use Disorder - drug therapy ; Tobacco Use Disorder - metabolism ; Tobacco Use Disorder - physiopathology ; Up-Regulation - drug effects ; Up-Regulation - physiology</subject><ispartof>The European journal of neuroscience, 2007-05, Vol.25 (10), p.3099-3108</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c5026-d53b9a2b21a5f9b3b85816f57851384f57d5932b01d898b26f66a24b238693413</citedby><cites>FETCH-LOGICAL-c5026-d53b9a2b21a5f9b3b85816f57851384f57d5932b01d898b26f66a24b238693413</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fj.1460-9568.2007.05546.x$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fj.1460-9568.2007.05546.x$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,778,782,1414,27907,27908,45557,45558</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/17561823$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Paterson, Neil E.</creatorcontrib><creatorcontrib>Balfour, David J.</creatorcontrib><creatorcontrib>Markou, Athina</creatorcontrib><title>Chronic bupropion attenuated the anhedonic component of nicotine withdrawal in rats via inhibition of dopamine reuptake in the nucleus accumbens shell</title><title>The European journal of neuroscience</title><addtitle>Eur J Neurosci</addtitle><description>Bupropion, a dopamine reuptake inhibitor, is an effective therapy for smoking cessation, but the behavioral and neurochemical mechanisms mediating its antismoking properties are relatively unknown. To explore the hypothesis that bupropion ameliorates nicotine withdrawal partly by a dopamine‐dependent mechanism, we investigated the effects of chronic bupropion on potassium‐stimulated dopamine overflow in the nucleus accumbens shell in nicotine‐withdrawing rats. We also assessed the effects of chronic bupropion on behavioral aspects of nicotine withdrawal measured by elevations in brain reward thresholds and somatic signs of withdrawal. Rats were treated with nicotine or saline for 7 days and then coadministration of bupropion or saline was initiated. After 14 days of coadministration of bupropion/saline and nicotine/saline, nicotine/saline administration was terminated, whereas bupropion/saline administration continued. These conditions mimic bupropion administration in human smokers. Cessation of nicotine administration in non‐bupropion‐treated rats elevated reward thresholds reflecting a reward deficit, increased somatic signs and diminished potassium‐evoked dopamine overflow in the nucleus accumbens shell. Chronic bupropion lowered reward thresholds and increased potassium‐evoked dopamine release regardless of previous nicotine exposure, possibly by inhibition of dopamine reuptake, and thus attenuated the anhedonic and neurochemical effects of nicotine withdrawal. Chronic bupropion blocked withdrawal‐associated increased somatic signs. Finally, acute experimenter‐administered nicotine enhanced brain reward function equally in all groups, indicating that bupropion does not alter the reward‐facilitating effects of experimenter‐administered nicotine. In conclusion, the bupropion‐induced increase in extracellular dopamine in the nucleus accumbens shell may ameliorate the anhedonia associated with nicotine withdrawal, which in turn may facilitate smoking cessation.</description><subject>Animals</subject><subject>brain reward function</subject><subject>Bupropion - pharmacology</subject><subject>Bupropion - therapeutic use</subject><subject>chronic bupropion</subject><subject>Dopamine - metabolism</subject><subject>Dopamine Uptake Inhibitors - pharmacology</subject><subject>Dopamine Uptake Inhibitors - therapeutic use</subject><subject>Drug Administration Schedule</subject><subject>extracellular dopamine</subject><subject>Male</subject><subject>nicotine withdrawal</subject><subject>Nucleus Accumbens - drug effects</subject><subject>Nucleus Accumbens - metabolism</subject><subject>nucleus accumbens shell</subject><subject>Potassium - pharmacology</subject><subject>rat</subject><subject>Rats</subject><subject>Rats, Wistar</subject><subject>Reward</subject><subject>Substance Withdrawal Syndrome - drug therapy</subject><subject>Substance Withdrawal Syndrome - metabolism</subject><subject>Substance Withdrawal Syndrome - physiopathology</subject><subject>Synaptic Transmission - drug effects</subject><subject>Synaptic Transmission - physiology</subject><subject>Tobacco Use Disorder - drug therapy</subject><subject>Tobacco Use Disorder - metabolism</subject><subject>Tobacco Use Disorder - physiopathology</subject><subject>Up-Regulation - drug effects</subject><subject>Up-Regulation - physiology</subject><issn>0953-816X</issn><issn>1460-9568</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2007</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqNkU-P1CAYxonRuOPqVzCcvLXyp1B68GAm66hZVxM1eiPQ0pTZFipQZ_aL-HmlO5P1KhfewO954H0fACBGJc7r9b7EFUdFw7goCUJ1iRireHl8BDYPF4_BBjWMFgLznxfgWYx7hJDgFXsKLnDNOBaEbsCf7RC8sy3Uyxz8bL2DKiXjFpVMB9NgoHKD6e6R1k-zd8Yl6HuYD3yyzsCDTUMX1EGN0DoYVIrwt1W5Hqy2aTXMdOdnNa10MMuc1K1Z2dXdLe1olghV2y6TNi7COJhxfA6e9GqM5sV5vwTf3119274vrj_vPmzfXhctQ4QXHaO6UUQTrFjfaKoFy-32rBYMU1HlomMNJRrhTjRCE95zrkilCRW8oRWml-DVyTc3_2sxMcnJxjZ_QDnjlygJYoQTWmdQnMA2-BiD6eUc7KTCncRIrpnIvVxHL9fRyzUTeZ-JPGbpy_Mbi55M9094DiEDb07AwY7m7r-N5dXHm7XK-uKktzGZ44NehVvJa1oz-eNmJz_hese-ftnKHf0LISasaA</recordid><startdate>200705</startdate><enddate>200705</enddate><creator>Paterson, Neil E.</creator><creator>Balfour, David J.</creator><creator>Markou, Athina</creator><general>Blackwell Publishing Ltd</general><scope>BSCLL</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7TK</scope></search><sort><creationdate>200705</creationdate><title>Chronic bupropion attenuated the anhedonic component of nicotine withdrawal in rats via inhibition of dopamine reuptake in the nucleus accumbens shell</title><author>Paterson, Neil E. ; Balfour, David J. ; Markou, Athina</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c5026-d53b9a2b21a5f9b3b85816f57851384f57d5932b01d898b26f66a24b238693413</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2007</creationdate><topic>Animals</topic><topic>brain reward function</topic><topic>Bupropion - pharmacology</topic><topic>Bupropion - therapeutic use</topic><topic>chronic bupropion</topic><topic>Dopamine - metabolism</topic><topic>Dopamine Uptake Inhibitors - pharmacology</topic><topic>Dopamine Uptake Inhibitors - therapeutic use</topic><topic>Drug Administration Schedule</topic><topic>extracellular dopamine</topic><topic>Male</topic><topic>nicotine withdrawal</topic><topic>Nucleus Accumbens - drug effects</topic><topic>Nucleus Accumbens - metabolism</topic><topic>nucleus accumbens shell</topic><topic>Potassium - pharmacology</topic><topic>rat</topic><topic>Rats</topic><topic>Rats, Wistar</topic><topic>Reward</topic><topic>Substance Withdrawal Syndrome - drug therapy</topic><topic>Substance Withdrawal Syndrome - metabolism</topic><topic>Substance Withdrawal Syndrome - physiopathology</topic><topic>Synaptic Transmission - drug effects</topic><topic>Synaptic Transmission - physiology</topic><topic>Tobacco Use Disorder - drug therapy</topic><topic>Tobacco Use Disorder - metabolism</topic><topic>Tobacco Use Disorder - physiopathology</topic><topic>Up-Regulation - drug effects</topic><topic>Up-Regulation - physiology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Paterson, Neil E.</creatorcontrib><creatorcontrib>Balfour, David J.</creatorcontrib><creatorcontrib>Markou, Athina</creatorcontrib><collection>Istex</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Neurosciences Abstracts</collection><jtitle>The European journal of neuroscience</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Paterson, Neil E.</au><au>Balfour, David J.</au><au>Markou, Athina</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Chronic bupropion attenuated the anhedonic component of nicotine withdrawal in rats via inhibition of dopamine reuptake in the nucleus accumbens shell</atitle><jtitle>The European journal of neuroscience</jtitle><addtitle>Eur J Neurosci</addtitle><date>2007-05</date><risdate>2007</risdate><volume>25</volume><issue>10</issue><spage>3099</spage><epage>3108</epage><pages>3099-3108</pages><issn>0953-816X</issn><eissn>1460-9568</eissn><abstract>Bupropion, a dopamine reuptake inhibitor, is an effective therapy for smoking cessation, but the behavioral and neurochemical mechanisms mediating its antismoking properties are relatively unknown. To explore the hypothesis that bupropion ameliorates nicotine withdrawal partly by a dopamine‐dependent mechanism, we investigated the effects of chronic bupropion on potassium‐stimulated dopamine overflow in the nucleus accumbens shell in nicotine‐withdrawing rats. We also assessed the effects of chronic bupropion on behavioral aspects of nicotine withdrawal measured by elevations in brain reward thresholds and somatic signs of withdrawal. Rats were treated with nicotine or saline for 7 days and then coadministration of bupropion or saline was initiated. After 14 days of coadministration of bupropion/saline and nicotine/saline, nicotine/saline administration was terminated, whereas bupropion/saline administration continued. These conditions mimic bupropion administration in human smokers. Cessation of nicotine administration in non‐bupropion‐treated rats elevated reward thresholds reflecting a reward deficit, increased somatic signs and diminished potassium‐evoked dopamine overflow in the nucleus accumbens shell. Chronic bupropion lowered reward thresholds and increased potassium‐evoked dopamine release regardless of previous nicotine exposure, possibly by inhibition of dopamine reuptake, and thus attenuated the anhedonic and neurochemical effects of nicotine withdrawal. Chronic bupropion blocked withdrawal‐associated increased somatic signs. Finally, acute experimenter‐administered nicotine enhanced brain reward function equally in all groups, indicating that bupropion does not alter the reward‐facilitating effects of experimenter‐administered nicotine. In conclusion, the bupropion‐induced increase in extracellular dopamine in the nucleus accumbens shell may ameliorate the anhedonia associated with nicotine withdrawal, which in turn may facilitate smoking cessation.</abstract><cop>Oxford, UK</cop><pub>Blackwell Publishing Ltd</pub><pmid>17561823</pmid><doi>10.1111/j.1460-9568.2007.05546.x</doi><tpages>10</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0953-816X
ispartof The European journal of neuroscience, 2007-05, Vol.25 (10), p.3099-3108
issn 0953-816X
1460-9568
language eng
recordid cdi_proquest_miscellaneous_20526237
source MEDLINE; Wiley Online Library Journals Frontfile Complete
subjects Animals
brain reward function
Bupropion - pharmacology
Bupropion - therapeutic use
chronic bupropion
Dopamine - metabolism
Dopamine Uptake Inhibitors - pharmacology
Dopamine Uptake Inhibitors - therapeutic use
Drug Administration Schedule
extracellular dopamine
Male
nicotine withdrawal
Nucleus Accumbens - drug effects
Nucleus Accumbens - metabolism
nucleus accumbens shell
Potassium - pharmacology
rat
Rats
Rats, Wistar
Reward
Substance Withdrawal Syndrome - drug therapy
Substance Withdrawal Syndrome - metabolism
Substance Withdrawal Syndrome - physiopathology
Synaptic Transmission - drug effects
Synaptic Transmission - physiology
Tobacco Use Disorder - drug therapy
Tobacco Use Disorder - metabolism
Tobacco Use Disorder - physiopathology
Up-Regulation - drug effects
Up-Regulation - physiology
title Chronic bupropion attenuated the anhedonic component of nicotine withdrawal in rats via inhibition of dopamine reuptake in the nucleus accumbens shell
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-16T21%3A55%3A18IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Chronic%20bupropion%20attenuated%20the%20anhedonic%20component%20of%20nicotine%20withdrawal%20in%20rats%20via%20inhibition%20of%20dopamine%20reuptake%20in%20the%20nucleus%20accumbens%20shell&rft.jtitle=The%20European%20journal%20of%20neuroscience&rft.au=Paterson,%20Neil%20E.&rft.date=2007-05&rft.volume=25&rft.issue=10&rft.spage=3099&rft.epage=3108&rft.pages=3099-3108&rft.issn=0953-816X&rft.eissn=1460-9568&rft_id=info:doi/10.1111/j.1460-9568.2007.05546.x&rft_dat=%3Cproquest_cross%3E20526237%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=20526237&rft_id=info:pmid/17561823&rfr_iscdi=true